NSW ER Visits Tied to Unapproved Peptides Rose 43-Fold

Emergency departments across New South Wales, Australia, saw presentations linked to unapproved peptide use climb from five a month in July 2025 to 217 a month in September 2026, according to state health surveillance data reported this week, and one experimental weight-loss peptide accounted for seven in ten of them.

What the data shows

NSW Health's own surveillance figures, published Monday and reported by The Nightly and The Canberra Times, count 1,180 emergency-department presentations statewide between July 2025 and September 2026 that mentioned unapproved peptide use. The monthly count rose steadily over that period, from 5 to 217 — roughly a 43-fold increase.

About a quarter of the patients were 16 to 24 years old; another 32% were 25 to 34, and 26% were 35 to 44. Men made up 51% of presentations. The most common primary diagnoses were gastrointestinal (abdominal pain, nausea, vomiting), cardiovascular (chest pain) and allergic or anaphylactic reactions.

Of the named substances, retatrutide — an investigational peptide studied by Eli Lilly as a once-weekly injection that activates three hormone receptors at once (GIP, GLP-1 and glucagon) — accounted for 71% of presentations. Another 38% of patients used the generic term "peptide" or named other unapproved compounds, including BPC-157, GHK-Cu, TB-500 and CJC-1295; some products carry Therapeutic Goods Administration approval, but the state health department said many sold online do not and some may be unlawful to import, supply or advertise.

NSW Health Minister Ryan Park called the trend "particularly alarming," and Chief Health Officer Dr. Kerry Chant said a product's polish is no guide to its contents: "A professional looking website, a label, purity claim, reviews, or influencer endorsement is not proof of what is inside the product," she said, adding that strength and contents can vary between products carrying the same label.

Why one molecule shows up so often

Retatrutide is not approved anywhere in the world. In company-run Phase 3 trials, Eli Lilly has reported weight loss of up to 22.6% over 80 weeks in adults with obesity, alongside improvements in several cardiovascular risk markers, with a Biologics License Application planned for the first quarter of 2027, according to Manufacturing Chemist. Those same trials also reported that gastrointestinal effects — diarrhea, nausea and constipation — are the most common side effects of the drug class, consistent with how GIP, GLP-1 and glucagon receptor activity slows digestion.

That overlap matters for reading the NSW numbers: on-target gastrointestinal effects are an expected feature of this receptor combination in supervised trials, which is one reason they show up in the ED data too. But anaphylaxis and other allergic reactions are not a documented feature of retatrutide in Lilly's own trial reporting. A product sold outside pharmaceutical manufacturing controls can vary in purity, sterility and actual peptide content from vial to vial, which is the kind of variation the gray-market peptide trade has been separately documented to carry — a buyer has no way to know, from a label alone, whether a reaction traces back to the molecule itself or to what else came in the vial.

What's known and what isn't

This is surveillance data, not a clinical study, and it has real limits. NSW Health counted ED presentations where a clinician coded unapproved peptide use as relevant — it does not confirm what was actually injected, since none of these products go through the batch testing and chain-of-custody records that an approved drug or a documented research lot would carry. The 1,180 figure also reflects one state's hospital system over 15 months, so it is a lower bound on the broader pattern, not a national or global count, and it says nothing about how many people used these products without presenting to a hospital at all.

The data also can't separate cause from co-occurrence. A patient coded for peptide use who also drank, used another substance, or had an unrelated condition is still counted the same way a clean single-product case would be. And because the figures track reported product names rather than verified lab contents, the 71% attributed to retatrutide reflects what patients or records called it — not a laboratory confirmation that each vial contained that peptide at the expected concentration.

What this means for researchers

The gap this data exposes isn't about whether triple-hormone-receptor agonists work — Lilly's own trial program is answering that question in a controlled setting, with publicly reported dosing, adverse-event rates and a regulatory filing timeline. It's about what happens to the same chemistry once it's synthesized and sold outside that chain of custody, with no equivalent lot number, batch testing or published certificate of analysis standing behind the vial.

For anyone tracking the research-peptide market, the more useful number here may not be 71%, but 1,180: a count that exists only because a health system built the surveillance to notice the pattern. Most jurisdictions haven't, which means NSW's spike may be less an outlier than an early look at a trend other health systems simply aren't measuring yet.

If there's a silver lining in an otherwise grim chart, it's that the clearest fix — publishing what's actually in the vial — is also the cheapest one; nobody needed a 43-fold jump in ER visits to know that a label isn't a lab result.